within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG07_Begelomab;

model Begelomab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.3148148148148148e-09,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 5.9999999999999995e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 4e-05,
    k12 = 1.1574074074074074e-09,
    k21 = 1.1574074074074074e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Begelomab</td></tr><tr><td>ATC code:</td><td>L04AG07</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.06</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.2</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Begelomab is a monoclonal antibody directed against CD26, developed for immunosuppression in transplantation, particularly in steroid-refractory acute graft-versus-host disease (aGVHD). It has received orphan drug designation but is not widely approved or in routine use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies are available for begelomab in humans in the scientific literature as of June 2024. Estimated PK parameters for monoclonal antibodies of similar class are provided.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AG07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Begelomab;
